US20100279325A1

US20100279325A1 - Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis

Info

Publication number: US20100279325A1
Application number: US12/814,137
Authority: US
Inventors: Jan Nilsson
Original assignee: Forskarpatent I SYD AB
Current assignee: Abcentra LLC
Priority date: 2004-03-19
Filing date: 2010-06-11
Publication date: 2010-11-04
Also published as: WO2005090974A1; SE0400683D0; US20120301491A1; EP1756569A1; US8435532B2; US20070104725A1

Abstract

The present invention relates to the use of fibronectin, tenascin, collagens type I, III, VI and/or VIII modified by aldehyde or by glycosylation in ELISA for detection of antibodies in plasma and serum to diagnose atherosclerosis as well as the use of induction of tolerance and active as well as passive immunization against glycosylated or aldehydemodified fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis.

Description

PRIORITY INFORMATION

This application is a continuation of now abandoned U.S. Utility application Ser. No. 11/523,366 filed Sep. 19, 2006, which is a continuation of PCT application No. PCT/SE2005/000394, filed on Mar. 17, 2005, which claims priority to Swedish Application No. 0400683-9, filed on Mar. 19, 2004, all of which are incorporated herein by reference in their entireties.

TECHNICAL FIELD

The present invention relates to the use of certain connective tissue proteins or derivatives thereof for detection of antibodies in plasma and serum to diagnose atherosclerosis, as well as the use of antibodies against such connective tissue proteins or derivatives thereof produced by immunization or recombinant technique for detection of certain connective tissue proteins or derivatives thereof in plasma and serum to diagnose presence of unstable and rupture-prone atherosclerotic plaques.

BACKGROUND OF THE INVENTION

Atherosclerosis is a degenerative disease of medium- and large-sized arteries. It is the major cause of acute myocardial infarction, stroke and peripheral artery disease. The first stages of the disease are characterized by accumulation of cholesterol-loaded macrophages forming small fatty streaks on the inside of the arterial wall. Activation of a chronic inflammatory process within these fatty streaks leads to the formation of raised fibromuscular plaques with various degree of extracellular lipid and cell necrosis. In plaques with extensive cell death and inflammation the fibrous cap covering the core of lipid deposits becomes eroded increasing the risk for plaque rupture and thrombotic occlusion of the vessel, i.e. the major cause of acute clinical events.
The disease is initiated by accumulation of lipoproteins, primarily LDL, in the extracellular matrix of the arterial intima. This accumulation is caused by binding of positively charged amino acids in the LDL protein apo B-100 to negatively charged matrix glycoproteins. The entrapped LDL aggregates and becomes oxidized in response various enzymes and oxygen radicals present in the arterial wall. The oxidation of LDL is associated with formation of a number of highly reactive compounds such as aldehydes, lipid peroxides and oxysterols that will cause neighbouring endothelial cells to express adhesion molecules and activate an inflammatory response. As a result monocytes and T cells will infiltrate the affected intima and the monocytes will differentiate into macrophages expressing different types of scavenger receptors. These receptors effectively bind and mediate the uptake and removal of oxidized LDL from the extracellular matrix. The macrophages will subsequently express oxidized LDL antigens associated with HLA-DR receptors. Recognition of these antigens by specific T cells results in activation of an adaptive immune response against oxidized LDL. The important role of this immune response in the development of atherosclerosis is becoming increasingly recognized.
The oxidation of LDL is also associated with a degradation of apo B-100 into peptide fragments that are further modified by reaction aldehydes such as malondialdehyde (MDA) and 4-hydroxynonenal. These aldehyde-modified peptide fragments become major targets for the immune system and antibodies against MDA-modified apo B-100 fragments are frequently encountered in human plasma. The role of these immune responses remains to be fully characterized but animal experiments demonstrating that immunization with oxidized LDL inhibits the development of atherosclerosis suggest that at least some of these immune responses have a protective effect.

SUMMARY OF THE PRESENT INVENTION

As discussed above it is generally believed that the oxidation of LDL mainly occurs while LDL is bound to glycosaminoglycans and other extracellular matrix proteins in the arterial wall. However, a possibility that remains largely unexplored is that reactive aldehydes that are generated during LDL oxidation may not only react with apo B-100 but also with the extracellular matrix proteins to which the LDL is adhered. If this happens it is likely to result in fragmentation and aldehyde-modification also of the respective matrix protein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1 and 2 are graphs showing the presence of antibodies against DMA-modified extracellular matrix proteins in normal human plasma;

FIG. 3 is a graph showing inhibition of antibody binding with DMA-fibronectin, but not with native fibronectin and;

FIG. 4 includes graphs showing antibodies against MDA modified FN and fibronectin.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

The present invention in particular relates to the use of fibronectin, tenascin, collagens type I, III, VI and/or VIII modified by aldehyde or by glycosylation in ELISA for detection of antibodies in plasma and serum to diagnose atherosclerosis.
In a preferred embodiment the fibronectin, tenascin, collagens type I, III, VI and VIII have been modified by malondialdehyde.
A further preferred embodiment relates to the use of antibodies against glycosylated or aldehyde-modified fibronectin, tenascin, collagens type I, III, VI and VIII produced by immunization or recombinant technique for detection of aldehyde-modified or glycosylated fibronectin, tenascin, collagen type I, III, VI and/or VIII in plasma and serum to diagnose presence of unstable and rupture-prone atherosclerotic plaques.
A still further preferred embodiment relates to the use of labelled antibodies against glycosylated or aldehyde-modified fibronectin, tenascin, collagens type I, III, VI and/or VIII produced by immunization or recombinant technique in imaging of atherosclerotic plaques.
A further aspect of the invention relates to the use of induction of tolerance and active as well as passive immunization against glycosylated or aldehyde-modified fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis.
When an aldehyde-modification and fragmentation of extracellular matrix proteins occurs in atherosclerotic plaques it is an important part of the disease process. Like the aldehyde-modified fragments of apo B-100 also aldehyde-modified peptide sequences in extracellular matrix proteins may become targets for autoimmune responses. This will result in recruitment of macrophage releasing matrix-degrading enzymes and erosion of plaque connective tissue and increase the risk for plaque rupture. When so, an aldehyde modification of extracellular matrix proteins is a critical factor in development of plaque rupture and acute cardiovascular events. It also points to the possibility of developing novel therapies for atherosclerosis by manipulating these immune responses through passive or active immunization or by induction of tolerance depending on if the main effect of the immune response is atherogenic or atheroprotective.
The enzymatic degradation of aldehyde-modified matrix proteins is also associated with a release of such degradation products into the circulation. This is of importance because the presence of such proteins in the circulation may act as markers of emerging plaque instability. The availability of a marker for emerging plaque instability would be of considerable value in identifying patients at high risk for development of acute myocardial infarction and stroke. Several effective invasive and non-invasive therapies for unstable plaques have been clinically established, However, the challenge remains to identify subjects with unstable plaques before they suffer an acute event. In subjects suffering from an acute myocardial infarction up to 30% die before reaching the hospital.

Results

To provide initial indirect evidence for the existence of oxidative damages of extracellular matrix proteins in humans presence of immune response against aldehyde-modified extracellular matrix proteins was investigated by analyzing if antibodies against such proteins are present in human plasma.
The vascular extracellular matrix proteins fibronectin, tenascin, biglycan, decorin, collagen type I, III, VI and VIII were coated on the bottom of 96-well microtiter plates. The plates were subsequently washed in 0.05% Tween-20 and incubated with Superblock. Aldehyde-modification was achieved by incubation with 0.05M MDA for 37° C. for 3 hr. After washing in 0.05% Tween-20 the wells were incubated with human plasma (pooled from 50 healthy blood donors), rinsed and incubated with goat anti-human biotinylated IgM. Detection was performed using AP-conjugated streptavidin and NPP substrate.
The results obtained in the ELISA analyses demonstrated presence of antibodies against aldehyde-modified fibronectin, tenascin, collagen type I, III, VI and VIII, but not against aldehyde-modified biglycan and decorin in human plasma (FIGS. 1 and 2). These findings demonstrate that immune responses against vascular extracellular matrix proteins exist in humans. Accordingly, they also provide evidence for the existence of oxidative damages of extracellular matrix proteins.
The antibody assay may utilise any tissue and the determinations are made using any immuno-cyto-histochemical method, any immunoassay including, ELISA, Elispot, RIA and others any blotting technique, including Western blotting, Southern blotting and others, any bioassay, any tissue culture technique, RT-PCR, flow cytometry, cytometric bead array, DNA microarray and/or proteomics.
Additional preliminary experiments were done on immune responses against MDA modified fibronectin. It was found that preincubation of human plasma with MDA modified fibronectin inhibited antibody-binding in the ELISA demonstrating the specificity of the assay (FIG. 3).
Finally, a small pilot clinical study was performed to assess the role of immune responses against aldehyde-modified fibronectin in cardiovascular disease. The study group was recruited from the Malmö Diet Cancer Study and consisted of 26 subjects that developed an acute myocardial infraction during a 5-year follow up period and 26 healthy controls matched for age, sex and smoking. The level of antibodies against aldehyde-modified fibronectin was determined in plasma samples obtained at the baseline investigation. Antibodies against aldehyde-modified fibronectin tended to be higher among those that later developed a myocardial infarction whereas the levels of antibodies against native fibronectin were low an equally distributed between the two groups (FIG. 4).
There was also a trend for an association between antibodies against aldehyde-modified fibronectin and carotid artery intima media thickness (an indirect measure of the severity of atherosclerosis) in the study (r=0.20, p=0.11). These observations suggest that immune responses against aldehyde matrix proteins such as fibronectin may be involved in atherosclerosis and serve as markers of disease risk and severity. However, additional studies are required in order to establish this hypothesis.
For the induction of tolerance mucosal immunization is used, whereby an obtained activation of the immuno response or tolerance is dependent on the dose of antigen and has to be tested out, as such.
To provide for an active immunization antigen extracted proteins or synthetic peptide fragments. Theoretically recombinantly produced proteins and protein fragments can be used as well.
At passive immunization one may use either antibodies directed to whole proteins or to peptides.

Claims

1-4. (canceled)

5. The use of antibodies against glycosylated fibronectin, tenascin, collagens type I, III, VI and/or VIII produced by immunization or recombinant technique for detection of aldehyde-modified fibronectin, tenascin, collagen type I, III, VI and VIII in plasma and serum to diagnose presence of unstable and rupture-prone atherosclerotic plaques.

6. The use of antibodies against aldehyde-modified fibronectin, tenascin, collagens type I, III, VI and/or VIII produced by immunization or recombinant technique for detection of aldehyde-modified fibronectin, tenascin, collagen type I, III, VI and VIII in plasma and serum to diagnose presence of unstable and rupture-prone atherosclerotic plaques.

7. The use of labeled antibodies against glycosylated fibronectin, tenascin, collagens type I, III, VI and/or VIII produced by immunization or recombinant technique in imaging of atherosclerotic plaques.

8. The use of labeled antibodies against aldehyde-modified fibronectin, tenascin, collagens type I, III, VI and/or VIII produced by immunization or recombinant technique in imaging of atherosclerotic plaques.

9. The use of induction of tolerance against glycosylated fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis.

10. The use of induction of tolerance against aldehyde-modified fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis.

11. The use of active immunization against glycosylated fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis.

12. The use of active immunization against aldehyde-modified fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis.

13. The use of passive immunization against glycosylated fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis.

14. The use of passive immunization against aldehyde-modified fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis.

15. A method of detecting antibodies against aldehyde-modified fibronectin, tenacin or collagens type I, III, VI or VII in a plasma or serum sample to diagnose atherosclerosis, said method comprising detecting antibodies utilizing aldehyde-modified fibronectin, tenascin, collagens type I, III, VI or VIII, respectively, and wherein an increased presence of such antibodies in the sample compared to the level of such antibodies in plasma or serum from a healthy individual indicated that the sample has been obtained from an individual having arthrosclerosis.

16. The method according to claim 15, wherein the antibody assay is an ELISA.

17. The method according to claim 15, wherein the fibronectin, tenascin, collagens type I, III, VI and VIII have been modified by malondialdehyde.

18. The method according to claim 15, wherein the fibronectin, tenascin, collagens type I, III, VI and VIII have been modified by 4-hydroxynonenal